A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (Iressa) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy.
Phase of Trial: Phase III
Latest Information Update: 19 May 2011
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 May 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Aug 2007 Status change from recruiting to in progress